Huijuan Li1,2,3,4, Xing Xing5, Liang Yao6, Meixuan Li1,2,3,4, Yangqin Xun1,2,3,4, Peijing Yan7, Xinmin Yang8, Kehu Yang9,10,11,12. 1. School of Public Health, Evidence-Based Social Science Research Center, Lanzhou University, Lanzhou, China. 2. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. 3. Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China. 4. Chinese GRADE Centre, Lanzhou University, Lanzhou, China. 5. Gansu Chinese Medicine University, Lanzhou, China. 6. Chinese Medicine Faculty of Hong Kong Baptist University, Hong Kong, China. 7. Institute of Clinical Research and Evidence Based Medicine, Gansu Provincial Hospital, Lanzhou, China. 8. The Center of Endoscopic Surgery of 451 Hospital of PLA, Xian, China. 9. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China, kehuyangebm2006@126.com. 10. Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China, kehuyangebm2006@126.com. 11. Chinese GRADE Centre, Lanzhou University, Lanzhou, China, kehuyangebm2006@126.com. 12. Institute of Clinical Research and Evidence Based Medicine, Gansu Provincial Hospital, Lanzhou, China, kehuyangebm2006@126.com.
Abstract
OBJECTIVES: The aim of the study was to assess the quality of guidelines on irritable bowel syndrome (IBS) using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument and identify concordance of different commendations. MATERIALS AND METHODS: A systematic search was undertaken from inception to May 2018. Two reviewers independently selected the titles and abstracts. The guidelines included were assessed using the AGREE II instrument. The consistency of evaluations was calculated using intra-class correlation coefficients with 95% CI. RESULTS: From 994 records, 7 guidelines were included. Most of guidelines got a moderate score of AGREE II. The highest median scores were achieved for scope and purpose and clarity and presentation (69.4%), while the lowest median scores across guidelines were for applicability (50.0%). Most of the nonpharmacologic management recommendations for IBS were similar. However, there also existed some differences on pharmacologic between different guidelines. CONCLUSIONS: The guidelines on IBS varied in quality and there were discrepancies about recommendations and recommendation grades. There is some space to improvement the quality of methodological rigor in development and reporting within clinical guidelines.
OBJECTIVES: The aim of the study was to assess the quality of guidelines on irritable bowel syndrome (IBS) using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument and identify concordance of different commendations. MATERIALS AND METHODS: A systematic search was undertaken from inception to May 2018. Two reviewers independently selected the titles and abstracts. The guidelines included were assessed using the AGREE II instrument. The consistency of evaluations was calculated using intra-class correlation coefficients with 95% CI. RESULTS: From 994 records, 7 guidelines were included. Most of guidelines got a moderate score of AGREE II. The highest median scores were achieved for scope and purpose and clarity and presentation (69.4%), while the lowest median scores across guidelines were for applicability (50.0%). Most of the nonpharmacologic management recommendations for IBS were similar. However, there also existed some differences on pharmacologic between different guidelines. CONCLUSIONS: The guidelines on IBS varied in quality and there were discrepancies about recommendations and recommendation grades. There is some space to improvement the quality of methodological rigor in development and reporting within clinical guidelines.
Authors: Nessmah Sultan; Jane E Varney; Emma P Halmos; Jessica R Biesiekierski; Chu K Yao; Jane G Muir; Peter R Gibson; Caroline J Tuck Journal: J Neurogastroenterol Motil Date: 2022-07-30 Impact factor: 4.725